|
| Press Releases |
|
 |
|
| Monday, December 2, 2024 |
|
|
Everest Medicines Announces Acceptance of VELSIPITY New Drug Application in Hong Kong |
| Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that Department of Health of the Government of the Hong Kong Special Administrative Region, China, has accepted Everests New Drug Application (NDA) for VELSIPITY (etrasimod) for the treatment of adult patients with moderately to severely active ulcerative colitis. more info >> |
|
| Friday, November 29, 2024 |
|
|
NEFECON(R) Included in National Reimbursement Drug List (NRDL) |
| On November 28, the National Healthcare Security Administration (NHSA) and the Ministry of Human Resources and Social Security announced the 'National Reimbursement Drug List (2024)' (NRDL), which will officially take effect on January 1, 2025. NEFECON(R), the first etiological treatment for IgA nephropathy developed by Everest Medicines, was successfully included in the NRDL. more info >> |
|
| Tuesday, November 19, 2024 |
|
|
Everest Medicines Announces NEFECON(R)'s Full Approval in South Korea |
| Today, Everest Medicines announced that NEFECON(R) has received full approval from the Ministry of Food and Drug Safety (MFDS) in South Korea, indicated for the treatment of adults with primary immunoglobulin A nephropathy (IgAN) with a urine protein excretion =1.0 g/day (or urine protein-to-creatinine ratio =0.8 g/g). This approval further expands NEFECON(R)'s footprint in Asia and provides Asian patients with a groundbreaking etiological treatment option for IgAN. more info >> |
|
| Friday, October 25, 2024 |
|
|
Everest Medicines Announces the Launch of VELSIPITY(R) in the Guangdong-Hong Kong-Macau Greater Bay Area |
| Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that, through the "Hong Kong and Macau Medicine and Equipment Connect" policy, VELSIPITY(R) has officially been approved for patients with moderately to severely active ulcerative colitis (UC) by the Guangdong Provincial Medical Products Administration and can first be used in the Foshan Fosun Chancheng Hospital and the First Affiliated Hospital of Sun Yat-sen University, two of the medical institutions designated by the "Hong Kong and Macau Medicine and Equipment Connect" policy in the Greater Bay Area. more info >> |
|
| Tuesday, October 22, 2024 |
|
|
Everest Medicines Announces Positive Results of Complete Chinese Subpopulation Data from the NEFECON Global Phase 3 NefIgArd Clinical Trial |
| Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that the "Kidney 360" magazine has published the complete two-year subpopulation data from Chinese patients in the Phase 3 NefIgArd clinical trial of NEFECON under the title "Efficacy and Safety of Nefecon in Patients With Immunoglobulin A Nephropathy From Mainland China: 2-Year NefIgArd Trial Results". more info >> |
|
| Monday, October 21, 2024 |
|
|
Everest Medicines Announces Taiwan TFDA Approval of NEFECON for the Treatment of Primary IgA Nephropathy |
| Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announces that the Taiwan Food and Drug Administration (TFDA) has approved NEFECON indicated "to reduce the loss of kidney function in adult patients with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression1". There are no restrictions on initial proteinuria levels in the approved indication. more info >> |
|
| Friday, October 18, 2024 |
|
|
Everest Medicines' Stock Price Rises by 20% as Profit Potential Drives Valuation Recovery |
| Everest Medicines (1952.HK) closed today with a 20.46% increase, hitting a high of HKD 28.6. The company's stock price has been steadily rising since the release of its interim results, with today's trading volume reaching HKD 291 million. Market updates show that BOCOM International released a report assigning an 'outperform' rating to the Chinese pharmaceutical sector, with Everest Medicines being one of the key recommended stocks. more info >> |
|
| Wednesday, October 2, 2024 |
|
|
NEFECON Included in 2024 KDIGO Clinical Practice Guidelines |
| Recently, Everest Medicines has announced another positive development. The company's lead product, NEFECON, as the only in-disease IgA nephropathy (IgAN) treatment, has been included in the "KDIGO 2024 Clinical Practice Guideline for the Management Of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV) (Public Review Draft)" (hereinafter referred to as the "New Guidelines (Draft)"), recommending treatment with a 9-month course of NEFECON for patients who are at risk of progressive kidney function loss with IgAN (2B). more info >> |
|
| Thursday, August 22, 2024 |
|
|
Everest Medicines Announces the Initiation of an Investigator-Initiated Clinical Trial (IIT) |
| Everest Medicines (HKEX 1952.HK, 'Everest', or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced the launch of an Investigator-Initiated Clinical Trial (IIT) for a personalized mRNA cancer vaccine, EVM16, under the study EVM16CX01, at the Peking University Cancer Hospital and Fudan University's Cancer Hospital. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
20 Start-ups Showcase at Hong Kong Tech Pavilion in VivaTech 2025
Jun 3, 2025 11:57 HKT/SGT
|
|
|
Anime Tokyo Station Launches Official YouTube Channel
Jun 3, 2025 11:00 JST
|
|
|
New HKTDC Chairman Professor Frederick Ma Si-Hang meets with management team
Jun 3, 2025 09:35 HKT/SGT
|
|
|
NEXX Signs Joint Memorandums of Understanding (MoU) with Milaha and KEC 
Jun 3, 2025 09:33 HKT/SGT
|
|
|
Shiv Khera's New Book "Live While You're Alive" Launched in Singapore
Jun 3, 2025 08:30 HKT/SGT
|
|
|
Luxren Capital Introduces a New Era in Mobile Trading: Secure, Regulated, and Always at Users' Fingertips
Jun 3, 2025 05:00 HKT/SGT
|
|
|
IFEX Capital Introduces Its Latest Version of a Groundbreaking Trading Platform Connecting Traders Globally
Jun 2, 2025 22:00 HKT/SGT
|
|
|
New Habitat for Humanity report shows housing improvements in informal settlements promotes health outcomes of women
Jun 2, 2025 19:00 HKT/SGT
|
|
|
Transgene and NEC Present Durable Disease-Free Survival and Sustained T Cell Responses at 24 months with Individualized Cancer Vaccine TG4050
Jun 2, 2025 17:56 JST
|
|
|
Eisai to Launch "Pariet S," the First Proton Pump Inhibitor RX-to-OTC in Japan
Jun 2, 2025 17:46 JST
|
|
|
Mitsubishi Corporation to Invest and Enter into a Business Partnership with DEScycle Ltd., a UK Company Developing Innovative Metal Recycling Technology
Jun 2, 2025 14:35 JST
|
|
|
MyJCB App Wins Gold at A' Design Award & Competition
Jun 2, 2025 12:00 JST
|
|
|
Fujitsu Technology Park's redevelopment project launch
Jun 2, 2025 11:23 JST
|
|
|
Wasion Holdings Subsidiaries Secure Over HK$253 Million in Contracts from State Grid's 2025 First Metering Equipment Tender
Jun 2, 2025 09:43 HKT/SGT
|
|
|
TransNusa Increases Scheduled Flight Frequency to Twice Daily
Jun 2, 2025 08:30 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
